Cystic fibrosis pulmonary exacerbation: Difference between revisions

From IDWiki
(Imported from text file)
 
No edit summary
 
(2 intermediate revisions by the same user not shown)
Line 1: Line 1:
== Clinical Presentation ==
== Background ==

* Respiratory exacerbation of chronic [[cystic fibrosis]]

== Clinical Manifestations ==


* Increased cough and sputum production
* Increased cough and sputum production
Line 8: Line 12:


* Get sputum cultures
* Get sputum cultures
* See [[Cystic fibrosis (CF) antibiotic dosing]]
* See [[Cystic fibrosis antibiotic dosing|antibiotic dosing in cystic fibrosis]]
* ''Burkholderia cepacia''
* [[Burkholderia cepacia complex|Burkholderia cepacia]]
** Most important organism to cover, if present
** Most important organism to cover, if present
** Meropenem, ceftazidime, tobi, doxy, Septra, levo
** [[Meropenem]], [[ceftazidime]], inhaled [[tobramycin]], [[doxycycline]], [[TMP-SMX]], [[levofloxacin]]
* ''Pseudomonas''
* [[Pseudomonas aeruginosa]]
** Double coverage
** Double coverage
** Beta-lactam plus another (quinolone, colistin, chloramphenicol, aminoglycoside)
** Beta-lactam plus another ([[fluoroquinolone]], [[colistin]], [[chloramphenicol]], [[aminoglycoside]])
** Treat for 10-14 days and repeat FPTs
** Treat for 10-14 days and repeat FPTs
* ''Stenotrophomonas''
* [[Stenotrophomonas maltophilia|Stenotrophomonas]]
** Septra, doxycycline, tigecycline, colistin, sometimes levofloxacin
** [[TMP-SMX]], [[doxycycline]], [[tigecycline]], [[colistin]], sometimes [[levofloxacin]]
* ''Staph. aureus''
* [[Staphylococcus aureus]]
** MSSA: cloxacillin, ceftazidime, Septra, doxycycline, meropenem
** MSSA: [[cloxacillin]], [[ceftazidime]], [[TMP-SMX]], [[doxycycline]], [[meropenem]]
** MRSA: vancomycin, tigecycline, linezolid, daptomycin, doxycycline, Septra
** MRSA: [[vancomycin]], [[tigecycline]], [[linezolid]], [[daptomycin]], [[doxycycline]], [[TMP-SMX]]


[[Category:Respirology]]
[[Category:Respirology]]

Latest revision as of 15:13, 20 June 2023

Background

Clinical Manifestations

  • Increased cough and sputum production
  • Increased dyspnea
  • Poor appetite, weight loss, occasionally fever, fatigue, reduction in pulmonary function, increased hemoptysis, change in chest radiographic findings, or change in chest physical examination findings (increased rales or rhonchi, decreased air exchange, increased use of accessory muscles of respiration)

Management